Recordati stock trades above takeover offer as investors weigh premium

Published on 09/16/2026 at 11:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Recordati stock closed at EUR 52.00 on Euronext Milan on September 11, 2026, modestly above the EUR 51.29 per share takeover offer from Respighi BidCo. The acceptance window runs until October 15, 2026, giving shareholders time to assess the bid premium and strategic upside.

Moderne Pharma-Produktionsanlage mit Edelstahltanks und Glasfassade bei Tageslicht — Recordati S.p.A. (IT0003828271) betreibt moderne Pharma-Produktionsanlagen mit hochwertiger Fertigungstechnik am Firmensitz in Mailand, Italien, Illustration mit AI erstellt.

Recordati stock (ISIN IT0003828271) finished a recent completed session at EUR 52.00 on Euronext Milan on September 11, 2026, slightly above the EUR 51.29 per share voluntary takeover offer on the table and signaling that investors are pricing in some upside beyond the bid price, according to Ad-hoc-news.

Takeover bid sets the tone

The central catalyst for Recordati stock in mid-September 2026 is a voluntary full takeover bid launched by Respighi BidCo, a vehicle of CVC Capital Partners and Groupe Bruxelles Lambert (GBL), at EUR 51.29 per share for Recordati’s ordinary shares, as reported by Ad-hoc-news.

According to the same overview on Ad-hoc-news, the acceptance window for the offer began on August 31, 2026 and is scheduled to close on October 15, 2026, giving shareholders several more weeks to decide whether to tender their shares into the bid.

Stock trades at a premium to the offer

Market data compiled in early September 2026 indicate that Recordati shares closed at EUR 52.00 on Euronext Milan on September 11, 2026, unchanged on the day, leaving the daily percent change at 0.00 percent, as noted by Ad-hoc-news.

The same source reports that on September 14, 2026 Recordati shares were quoted at about EUR 52.25 on Euronext Milan, modestly above both the September 11, 2026 close and the EUR 51.29 per share offer, implying a market premium of roughly 1.9 percent to the bid price and suggesting that investors expect either a higher bid or that the company has standalone value exceeding the current proposal, according to Ad-hoc-news.

Strategic context and growth initiatives

Beyond the takeover situation, Recordati’s strategic positioning in rare diseases and specialty pharmaceuticals remains a key part of the equity story. As Markets Insider reported on September 15, 2026, Recordati led an interim financing round for Orvida Pharma, a clinical-stage biotechnology company developing treatments for rare and severe genetic skin diseases, underlining its commitment to expanding its rare diseases franchise.

The same report notes that Recordati, headquartered in Milan and listed on the Italian Stock Exchange under the ticker REC, is an international pharmaceutical group with a dedicated Rare Diseases business, reinforcing the strategic rationale for private equity interest in the company’s long-term growth potential, according to Markets Insider.

Price level and market metrics

For orientation, Recordati stock most recently finished a completed session at EUR 52.00 on Euronext Milan on September 11, 2026, matching the prior day’s settlement and leaving the daily percent change at 0.00 percent, as highlighted in a data overview by Ad-hoc-news.

That same overview characterizes Recordati stock as modestly positive year to date at about 7.13 percent in a volatile European equity environment, giving investors a sense of how the current takeover premium fits into a broader performance context, according to Ad-hoc-news.